Krechler T, Novotný J, Zeman M, Krska Z, Svestka T, Sváb J, Lukás M, Filipová R, Zák A
IV. interní klinika 1. LF UK a VFN, Praha.
Cas Lek Cesk. 2004;143(2):97-100.
The aim of the present study was to evaluate the relationship between Pancreatic Cancer and Type 2 Diabetes Mellitus, which represents a higher risk of many human tumors. In patients with Pancreatic Cancer, Type 2 Diabetes Mellitus occurs approximately in 30%.
Fifty patients with newly diagnosed Pancreatic Cancer were analysed in a retrospective pilot study where the staging of the tumor and the case history of the patients were studied. This data were compared in three groups of patients: the control group without diabetes, one with Impaired Fasting Glucose, and patients with Diabetes Mellitus. Incidence of Diabetes Mellitus and that of Impaired Fasting Glucose were also followed in patients with Pancreatic Cancer and Colorectal Cancer. The retrospective study confirmed the late diagnosis of Pancreatic Cancer. The tumors were actually in clinical stage IV in 50% of the patients. Diabetes Mellitus was present in 34% of patients with Pancreatic Cancer; in 44% of these patients the Impaired Fasting Glucose was also diagnosed while the normal glucose status was seen in 22% of patients. Incidence of Impaired Fasting Glucose and that of Diabetes Mellitus in groups of patients with Pancreatic Cancer and Colorectal Cancer was studied. Diabetes Mellitus was present in 12.5% patients with Colorectal Cancer.
In spite of modern diagnostic methods, the early diagnosis of Pancreatic Cancer remains a great problem. Incidence of Diabetes Mellitus in patients with Pancreatic Cancer was significantly higher in comparison with the Colorectal Cancer group (P0.01). A significant number of patients with Impaired Fasting Glucose were also present in the group with Pancreatic Cancer. Analysis of the relationships between Pancreatic Cancer and Impaired Glucose Metabolism could contribute to the early diagnosis of this serious malignant disease.
本研究旨在评估胰腺癌与2型糖尿病之间的关系,2型糖尿病是许多人类肿瘤发生风险较高的因素。在胰腺癌患者中,2型糖尿病的发生率约为30%。
在一项回顾性初步研究中,对50例新诊断的胰腺癌患者进行了分析,研究了肿瘤分期和患者病史。将这些数据在三组患者中进行比较:无糖尿病的对照组、空腹血糖受损组和糖尿病组。还对胰腺癌和结直肠癌患者的糖尿病发生率和空腹血糖受损发生率进行了跟踪。回顾性研究证实了胰腺癌的诊断较晚。实际上,50%的患者肿瘤处于临床IV期。34%的胰腺癌患者患有糖尿病;其中44%的患者同时被诊断为空腹血糖受损,而22%的患者血糖状态正常。研究了胰腺癌和结直肠癌患者组中空腹血糖受损发生率和糖尿病发生率。12.5%的结直肠癌患者患有糖尿病。
尽管有现代诊断方法,但胰腺癌的早期诊断仍然是一个大问题。与结直肠癌组相比,胰腺癌患者的糖尿病发生率显著更高(P<0.01)。胰腺癌组中也有相当数量的空腹血糖受损患者。分析胰腺癌与糖代谢受损之间的关系有助于早期诊断这种严重的恶性疾病。